Producer
Pall Corporation (Danaher)
US filtration technology company (Port Washington, NY; wholly-owned by Danaher Corporation since 2015 acquisition for $13.8B; Danaher NYSE: DHR; ~$20B revenue). Pall is the world's second-largest pharmaceutical sterilizing filtration manufacturer with an estimated ~30% global market share. Key sterilizing membrane products: Supor (PES — polyethersulfone) membranes for high-protein and buffer applications; Fluorodyne (PVDF) for aggressive chemical compatibility. Filter devices include Kleenpak Nova, Ultipor N66, and Palltronic AerVent vent filters. Pall serves biopharma, biotechnology, food & beverage, and industrial sectors from the same filtration platform. Primary pharma manufacturing at Pensacola, FL and Fajardo, Puerto Rico. Danaher's simultaneous ownership of Pall (filtration, 30% biopharma market) AND Cytiva (chromatography resins and bioreactors, ~40% market) gives a single US industrial conglomerate unmatched consolidated control over the biopharmaceutical manufacturing consumables supply chain — a concentration with no historical precedent in the pharmaceutical equipment sector.
1
Inputs supplied
1
Goods downstream
2
Facilities
0
Stories
What they make
1 input Pall Corporation (Danaher) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Pall Corporation (Danaher) makes, pick one to see the full supply chain.
Where they make it
2 facilities
Pall Corporation Membrane Manufacturing (Fajardo, Puerto Rico) →
USPuerto Rico · manufacturing
Pall Corporation (Danaher) pharmaceutical filtration manufacturing facility in Fajardo, Puerto Rico. Puerto Rico is a major hub for US pharmaceutical manufacturing — more than 80 FDA-approved pharmaceutical facilities operate on the island. Fajardo supplies Pall sterilizing membrane products to Puerto Rico's pharmaceutical manufacturing cluster (including major Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb, and Abbott facilities). Hurricane Maria (September 2017) caused catastrophic disruption to Puerto Rico's pharmaceutical manufacturing ecosystem; the Pall Fajardo facility, along with dozens of drug manufacturers, faced extended power outages and supply disruptions that rippled through US drug supply chains for months. Source: https://www.pall.com/en/about-pall/manufacturing-locations.html
Pall Corporation Membrane Manufacturing (Pensacola, FL) →
USFlorida · manufacturing
Pall Corporation (Danaher) primary membrane manufacturing facility in Pensacola, FL producing Supor (PES) and Fluorodyne (PVDF) pharmaceutical-grade sterilizing membranes. Pensacola is Pall's largest US pharmaceutical filtration manufacturing site, serving the North American biopharmaceutical manufacturing customer base. The Pensacola facility is in the Gulf Coast hurricane zone — Category 3-5 hurricane risk has historically affected pharmaceutical supply chain planning for Pall customers. Ivan (2004) and Sally (2020) caused significant damage to Pensacola industrial facilities. Pall experienced documented production disruptions during major Gulf Coast storm events. Source: https://www.pall.com/en/about-pall/manufacturing-locations.html
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Life Sciences (Pharma, Bioprocess)
50%Food & Beverage Filtration
20%Industrial Filtration (Energy, Chemical)
20%Aerospace & Defense Filtration
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Concentration2023
Danaher Corporation (Washington DC; NYSE: DHR; ~$24B revenue) owns both Pall Corporation (filtration, ~30% of global pharmaceutical sterilizing membranes; acquired 2015 for $13.8B) and Cytiva (chromatography resins including MabSelect Protein A for antibody purification, bioreactors, cell culture media; acquired 2020 from GE Healthcare for $21.4B). Combined, Danaher's bioprocessing companies are estimated to hold 35-45% of the overall biopharmaceutical manufacturing consumables market — spanning sterilizing filtration, depth filtration, protein A chromatography, ion exchange chromatography, tangential flow filtration, bioreactors, and cell culture media. This means that a single American industrial conglomerate controls the critical consumables for every major unit operation in a biologics manufacturing process: growing cells (Cytiva bioreactors), feeding them (Cytiva cell culture media), purifying the drug substance (Cytiva chromatography resins), and sterilizing the final drug solution (Pall filtration). No historical precedent exists for a single company achieving this level of embedded supply control over biopharmaceutical manufacturing inputs. A Danaher acquisition by a foreign sovereign wealth fund or private equity firm hostile to Western pharmaceutical supply chains would constitute a strategic threat to global vaccine and biologics manufacturing capacity with essentially no short-term remedy.
Danaher Corporation ↗Did you know2024
Pall's filtration membranes are used for: pharmaceutical sterile filtration (removing bacteria from injectable drugs), beer/wine/beverage clarification (removing yeast and particles from beverages), aircraft hydraulic fluid filtration (removing contamination from flight control systems), and gas turbine air filtration (protecting power generation turbines). The same filtration membrane technology and manufacturing science that ensures a sterile insulin injection also ensures a clear glass of beer AND ensures clean hydraulic fluid in an aircraft's flight control surfaces AND protects a power plant turbine. Four supply chains — pharmaceutical, beverage, aerospace, and energy — converge on the same Pall membrane manufacturing facilities and the same Danaher parent.
Pall Corporation / Danaher ↗Origin2023
Pall Corporation was founded in 1946 in Port Washington, New York by David Pall — a British scientist who had worked during WWII at the US Army Air Force developing filtration materials for aircraft hydraulic systems. After the war, Pall adapted his fluid filtration technology from military aerospace applications to pharmaceutical and industrial use. The filtration company that started with wartime aircraft hydraulic fluid purity grew into the world's second-largest pharmaceutical sterilizing filter manufacturer before being acquired by Danaher Corporation in 2015 for $13.8 billion — one of the largest specialty industrial acquisitions of the 2010s.
Pall Corporation / Danaher ↗